The role of ferric citrate in a sample of Iraqi patients on hemodialysis- A randomized controlled clinical trial-Reference-Cited by-同舟云学术

The role of ferric citrate in a sample of Iraqi patients on hemodialysis- A randomized controlled clinical trial

Published:2023-08-15 Issue:CSS 1 Volume:8 Page:1-18
ISSN:1390-9347
Container-title:Sumer 1
language:
Short-container-title:RB

Author:

Jassem Reyadh¹,Al-Hamadani Fadya²,Fakhri Al-Tukmag Haydar³,Hamza Al_mensory Saad John⁴

Affiliation:

1. 1Student in Clinical Pharmacy Department

2. 2Clinical Pharmacy Department at College of Pharmacy University of Baghdad

3. Baghdad College of Medical Sciences

4. Nephrologist Babylon Health Directorate Ministry of Health-Iraq

Abstract

Background: Uncontrolled hyperphosphatemia is the main difficulty facing staff treating patients with end-stage renal disease on hemodialysis. Sevelamer and calcium-containing phosphate binders have been associated with cost burden and tissue calcification, respectively. Therefore, the current trial was targeted to investigate the efficacy of a new phosphate binder, ferric citrate, in a sample of Iraqi patients with end-stage renal disease on hemodialysis. Keywords: Ferric citrate, Hemodialysis Phosphate binder

Publisher

Clinical Biotec

Subject

Infectious Diseases,Applied Microbiology and Biotechnology,Epidemiology,Biotechnology

Reference96 articles.

1. 1 Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: Assessing the current evidence linking

2. outcomes with treatment adherence. BMC Nephrol [Internet]. 2013 Jul 18 [cited 2022 Apr 3];14(1):1–9.

3. Available from: https://bmcnephrol.biomedcentral.com/articles/10.1186/1471-2369-14-153

4. 2 Drüeke TB. Hyperparathyroidism in Chronic Kidney Disease. Endotext [Internet]. Oct 18 [cited 2022

5. Apr 3]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK278975.2021.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of ferric citrate in a sample of Iraqi patients on hemodialysis- A randomized controlled clinical trial;Sumer 1;2023-08-15